The predicated demise of racemic new molecular entities is an exaggeration

Nature Reviews Drug Discovery

Volumn 11, Issue 12, 2012, Pages 972-973

  Agranat, Israel ^a   Wainschtein, Silvya R ^a,b   Zusman, Enav Z ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CHIRALITY; DRUG APPROVAL; ENANTIOMER; LETTER; PATENT; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOCHEMISTRY; STEREOISOMERISM;

DRUG APPROVAL; DRUG DISCOVERY; STEREOISOMERISM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84870829448     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3657-c1     Document Type: Letter

References (11)

1. Mullard, A. 2011 FDA drug approvals. Nature Rev. Drug Discov. 11, 91-94 (2012).
2. Agranat, I., Caner, H. & Caldwell, J. Putting chirality to work: the strategy of chiral switches. Nature Rev. Drug Discov. 1, 753-768 (2002).
3. Caner, H., Groner, E., Levy, L. & Agranat, I. Trends in the development of chiral drugs. Drug Discov. Today 9, 105-110 (2004).
4. Ariens, E. J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26, 663-668 (1984).
5. Federal Court, Canada. Apotex Inc. versus Sanofi- Aventis (2011 FC 1486); pages 226-228. Federal Court (Canada) [online], http://decisions.fct-cf.gc.ca/ en/2011/2011fc1486/2011fc1486.html (2011).
6. US FDA. FDA's policy statement for the development of new stereoisomeric drugs. FDA website [online], http://www.fda.gov/drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm122883.htm (1 May 1992).
7. Gal, J. in Chirality in Drug Research (eds Francotte, E. & Lindner, W.) 3-26 (Wiley-VCH, 2006).
8. Ellery, T. & Hansen, N. Pharmaceutical Lifecycle Management 160-161 (Wiley, 2012).
9. Branch, S. K. & Hutt, A. J. in Drug Stereochemistry: Analytical Methods and Pharmacology 3rd edn (eds Jozwiak, K., Lough, W. J. & Wainer, I. W.) 240-273 (Informa Healthcare, 2012).
10. Agranat, I. & Wainschtein, S. R. The strategy of enantiomer patents of drugs, Drug Discov. Today 15, 163-170 (2010).
11. Zusman, E. Z. The death of new racemic drugs was an exaggeration. (Student poster abstract) Drug Inf. J. 46, 497-498 (2012).